Abstract
Abstract Introduction: Reprimo is a highly glycosylated protein, inducing cell cycle G2 arrest. Reprimo promoter methylation has been reported as the mechanism regulating its expression in gastric cancer, but the biological roles remain unclear. The aim of this study is to examine Reprimo from a functional point of view. Methods: The methylation status of Reprimo promoter was analyzed using quantitative-methylation specific polymerase chain reaction (Q-MSP), and the effects of expression were examined in gastric cancer cell lines (AZ521 and SH10) with no endogenous expression of Reprimo using stable transfection and phenotype analysis (WST assay and apoptosis assay). Results: Reprimo methylation was detected in 6 of 8 gastric cancer cell lines; the silenced or reduced expression could be restored by treatment with demethylating agents such as 5-aza-2’-deoxycitidine and/or trichostatin A. On Q-MSP, the optimal cutoff value (0.42) determined by the receiver operating characteristic (ROC) curve could significantly discriminate primary tumor (69%, 57/83) from the corresponding normal tissues (18%, 15/83, P<0.0001). AZ521 cells with enforced expression significantly enhanced sensitivity to 5-FU therapy, and augmented apoptosis without affecting cell cycle. On the other hand, SH10 cells without methylation exhibited the undetectable level of endogenous expression, and Reprimo expression was robustly induced under 5-fluorouracil (5-FU), one of the standard anticancer agents for gastric cancer. As a result, SH10 cells stably transfected with Reprimo exhibited similar level apoptosis with mock cells. Conclusion: Reprimo expression is inducible under 5-FU agent, that may lead to apoptosis in gastric cancer. However, its expression is frequently suppressed by promoter methylation. Thus, Reprimo methylation status is considered to have a great potential as a predictive biomarker to select patients who may be effective for 5-FU therapy in gastric cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 180.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
